FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Neal Castagnoli

Research Profile

Chemicals & Drugs

Phenomena

Oxidation-Reduction

Concepts & Ideas

Physiology

Biotransformation

Living Beings

Anatomy

Co-author Network

Publications

TOP 3
Moa Andresen Bergström; Neal Castagnoli; Emre M Isin; Claire E Milne
Bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant.
Michelle L Grimm; William J Allen; Meghan Finn; Neal Castagnoli; James M Tanko
Reaction of benzophenone triplet with aliphatic amines. What a potent neurotoxin can tell us about the reaction mechanism.
Anél Pretorius; Modupe O Ogunrombi; Hendrik Fourie; Gisella Terre'Blanche; Neal Castagnoli; Jacobus J Bergh; Jacobus P Petzer
Interactions of 1-methyl-3-phenylpyrrolidine and 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane with monoamine oxidase B.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Neal Castagnoli (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Moa Andresen Bergström; Neal Castagnoli; Emre M Isin; Claire E Milne
Bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(10):1823-32.
2011: Michelle L Grimm; William J Allen; Meghan Finn; Neal Castagnoli; James M Tanko
Reaction of benzophenone triplet with aliphatic amines. What a potent neurotoxin can tell us about the reaction mechanism.
Bioorganic & medicinal chemistry 2011;19(4):1458-63.
2010: Anél Pretorius; Modupe O Ogunrombi; Hendrik Fourie; Gisella Terre'Blanche; Neal Castagnoli; Jacobus J Bergh; Jacobus P Petzer
Interactions of 1-methyl-3-phenylpyrrolidine and 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane with monoamine oxidase B.
Bioorganic & medicinal chemistry 2010;18(11):4111-8.
2010: Tove Johansson Mali'n; Lars Weidolf; Neal Castagnoli; Ulrik Jurva
P450-catalyzed vs. electrochemical oxidation of haloperidol studied by ultra-performance liquid chromatography/electrospray ionization mass spectrometry.
Rapid communications in mass spectrometry : RCM 2010;24(9):1231-40.
2010: Belinda Strydom; Sarel F Malan; Neal Castagnoli; Jacobus J Bergh; Jacobus P Petzer
Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues.
Bioorganic & medicinal chemistry 2010;18(3):1018-28.
2009: Elizna M Van der Walt; Erika M Milczek; Sarel F Malan; Dale E Edmondson; Neal Castagnoli; Jacobus J Bergh; Jacobus P Petzer
Inhibition of monoamine oxidase by (E)-styrylisatin analogues.
Bioorganic & medicinal chemistry letters 2009;19(9):2509-13.
2009: Clarina I Manley-King; Gisella Terre'Blanche; Neal Castagnoli; Jacobus J Bergh; Jacobus P Petzer
Inhibition of monoamine oxidase B by N-methyl-2-phenylmaleimides.
Bioorganic & medicinal chemistry 2009;17(8):3104-10.
2009: Jacobus P Petzer; Neal Castagnoli; Michael A Schwarzschild; Jiang-Fan Chen; Cornelis J Van Der Schyf
Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2009;6(1):141-51.
2008: Anél Pretorius; Modupe O Ogunrombi; Gisella Terre'Blanche; Neal Castagnoli; Jacobus J Bergh; Jacobus P Petzer
Deuterium isotope effects for the oxidation of 1-methyl-3-phenyl-3-pyrrolinyl analogues by monoamine oxidase B.
Bioorganic & medicinal chemistry 2008;16(19):8813-7.
2008: Judey Pretorius; Sarel F Malan; Neal Castagnoli; Jacobus J Bergh; Jacobus P Petzer
Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.
Bioorganic & medicinal chemistry 2008;16(18):8676-84.
2008: Neal Castagnoli; Philippe Bissel; Ulrik Jurva; Mehdi Ashraf-Khorasani
Electrochemical mass spectrometric studies on 1-cyclopropyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Rapid communications in mass spectrometry : RCM 2008;22(13):2089-96.
2008: Philippe Bissel; Ashraf Khalil; John M Rimoldi; Kazuo Igarashi; Dale E Edmondson; Anthony Miller; Neal Castagnoli
Stereochemical studies on the novel monoamine oxidase B substrates (1R,6S)- and (1S,6R)-3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane.
Bioorganic & medicinal chemistry 2008;16(7):3557-64.
2008: Modupe O Ogunrombi; Sarel F Malan; Gisella Terre'Blanche; Neal Castagnoli; Jacobus J Bergh; Jacobus P Petzer
Structure-activity relationships in the inhibition of monoamine oxidase B by 1-methyl-3-phenylpyrroles.
Bioorganic & medicinal chemistry 2008;16(5):2463-72.
2007: Modupe O Ogunrombi; Sarel F Malan; Gisella Terre'Blanche; Kay Castagnoli; Neal Castagnoli; Jacobus J Bergh; Jacobus P Petzer
Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline.
Life sciences 2007;81(6):458-67.
2007: Xiangzhong Li; Michelle L Grimm; Kazuo Igarashi; Neal Castagnoli; James M Tanko
The first calibration of an aminiumyl radical ion clock: why N-cyclopropylanilines may be poor mechanistic probes for single electron transfer.
Chemical communications (Cambridge, England) 2007;(25):2648-50.
2007: Deidré van den Berg; Kevin R Zoellner; Modupe O Ogunrombi; Sarel F Malan; Gisella Terre'Blanche; Neal Castagnoli; Jacobus J Bergh; Jacobus P Petzer
Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues.
Bioorganic & medicinal chemistry 2007;15(11):3692-702.
2006: Philippe Bissel; Skye Geherin; Kazuo Igarashi; Richard D Gandour; Iulia M Lazar; Neal Castagnoli
Mass spectrometric studies on 4-aryl-1-cyclopropyl-1,2-dihydropyridinyl derivatives: an examination of a novel fragmentation pathway.
Journal of mass spectrometry : JMS 2006;41(12):1643-53.
2006: Raphaël Frédérick; Willy Dumont; Fred Ooms; Lindsey Aschenbach; Cornelis J Van Der Schyf; Neal Castagnoli; Johan Wouters; Alain Krief
Synthesis, structural reassignment, and biological activity of type B MAO inhibitors based on the 5H-indeno[1,2-c]pyridazin-5-one core.
Journal of medicinal chemistry 2006;49(12):3743-7.
2006: Ashraf A Khalil; Bruce Davies; Neal Castagnoli
Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke.
Bioorganic & medicinal chemistry 2006;14(10):3392-8.
2006: Nevil Vlok; Sarel F Malan; Neal Castagnoli; Jacobus J Bergh; Jacobus P Petzer
Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC).
Bioorganic & medicinal chemistry 2006;14(10):3512-21.
2005: John M Rimoldi; Satish G Puppali; Emre Isin; Philippe Bissel; Ashraf Khalil; Neal Castagnoli
A novel and selective monoamine oxidase B substrate.
Bioorganic & medicinal chemistry 2005;13(20):5808-13.
2005: Ulrik Jurva; Philippe Bissel; Emre M Isin; Kazuo Igarashi; Simon Kuttab; Neal Castagnoli
Model electrochemical-mass spectrometric studies of the cytochrome P450-catalyzed oxidations of cyclic tertiary allylamines.
Journal of the American Chemical Society 2005;127(35):12368-77.
2005: Raphaël Frédérick; Fred Ooms; Neal Castagnoli; Jacobus P Petzer; Jiang-Fan Feng; Michael A Schwarzschild; Cornelis J Van Der Schyf; Johan Wouters
(E)-8-(3-Chlorostyryl)-1,3,7-trimethylxanthine, a caffeine derivative acting both as antagonist of adenosine A2A receptors and as inhibitor of MAO-B.
Acta crystallographica. Section C, Crystal structure communications 2005;61(Pt 9):o531-2.
2005: Philippe Bissel; Neal Castagnoli; Sarah Penich
Studies on the cytochrome P450 catalyzed oxidation of 13C labeled 1-cyclopropyl-4-phenyl-1,2,3,6-tetrahydropyridine by 13C NMR.
Bioorganic & medicinal chemistry 2005;13(8):2975-80.
2003: Neal Castagnoli; Jacobus P Petzer; Salome Steyn; Kay Castagnoli; Jiang-Fan Chen; Michael A Schwarzschild; Cornelis J Van Der Schyf
Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists.
Neurology 2003;61(11 Suppl 6):S62-8.
2003: Michael A Schwarzschild; Kui Xu; Emin Oztas; Jacobus P Petzer; Kay Castagnoli; Neal Castagnoli; Jiang-Fan Chen
Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
Neurology 2003;61(11 Suppl 6):S55-61.
2003: Aaron B Beeler; Rama Sarma V S Gadepalli; Salome Steyn; Neal Castagnoli; John M Rimoldi
Synthesis and in vitro biological evaluation of fluoro-substituted-4-phenyl-1,2,3,6-tetrahydropyridines as monoamine oxidase B substrates.
Bioorganic & medicinal chemistry 2003;11(23):5229-34.
2003: Francesco Bibbiani; Justin D Oh; Jacobus P Petzer; Neal Castagnoli; Jiang-Fan Chen; Michael A Schwarzschild; Thomas N Chase
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Experimental neurology 2003;184(1):285-94.
2003: Jacobus P Petzer; Salome Steyn; Kay Castagnoli; Jiang-Fan Chen; Michael A Schwarzschild; Cornelis J Van Der Schyf; Neal Castagnoli
Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.
Bioorganic & medicinal chemistry 2003;11(7):1299-310.
2003: Fred Ooms; Raphaël Frédérick; François Durant; Jacobus P Petzer; Neal Castagnoli; Cornelis J Van Der Schyf; Johan Wouters
Rational approaches towards reversible inhibition of type B monoamine oxidase. Design and evaluation of a novel 5H-Indeno[1,2-c]pyridazin-5-one derivative.
Bioorganic & medicinal chemistry letters 2003;13(1):69-73.
2003: Kay Castagnoli; J B Petzer; Salome Steyn; Cornelis J Van Der Schyf; Neal Castagnoli
Inhibition of human MAO-A and MAO-B by a compound isolated from flue-cured tobacco leaves and its neuroprotective properties in the MPTP mouse model of neurodegeneration.
Inflammopharmacology 2003;11(2):183-8.
2002: Jiang-Fan Chen; Salome Steyn; Roland Staal; Jacobus P Petzer; Kui Xu; Cornelis J Van Der Schyf; Kay Castagnoli; Patricia K Sonsalla; Neal Castagnoli; Michael A Schwarzschild
8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism.
The Journal of biological chemistry 2002;277(39):36040-4.
2002: Philippe Bissel; Mark C Bigley; Kay Castagnoli; Neal Castagnoli
Synthesis and biological evaluation of MAO-A selective 1,4-disubstituted-1,2,3,6-tetrahydropyridinyl substrates.
Bioorganic & medicinal chemistry 2002;10(9):3031-41.
2002: Neal Castagnoli; Kay Castagnoli; Géraldine Magnin; Simon Kuttab; Jackie Shang
Studies on the oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridines.
Drug metabolism reviews 2002;34(3):533-47.
2002: Helen J Crawford; Dennis McClain-Furmanski; Neal Castagnoli; Kay Castagnoli
Enhancement of auditory sensory gating and stimulus-bound gamma band (40 Hz) oscillations in heavy tobacco smokers.
Neuroscience letters 2002;317(3):151-5.
2001: Simon Kuttab; J Shang; Neal Castagnoli
Rat liver microsomal enzyme catalyzed oxidation of 4-phenyl-trans-1-(2-phenylcyclopropyl)-1,2,3,6-tetrahydropyridine.
Bioorganic & medicinal chemistry 2001;9(7):1685-9.
2001: James M Tanko; Robert Friedline; N K Suleman; Neal Castagnoli
tert-Butoxyl as a model for radicals in biological systems: caveat emptor.
Journal of the American Chemical Society 2001;123(24):5808-9.
2001: Emre M Isin; M de Jonge; Neal Castagnoli
Studies on synthetic approaches to 1H- and 2H-indazolyl derivatives.
The Journal of organic chemistry 2001;66(12):4220-6.
2001: Salome Steyn; Kay Castagnoli; Neal Castagnoli
Rescue of dying neurons by (R)-deprenyl in the MPTP-mouse model of Parkinson's disease does not include restoration of neostriatal dopamine.
Annals of the New York Academy of Sciences 2001;939():330-9.
2001: Jiang-Fan Chen; Kui Xu; Jacobus P Petzer; Roland Staal; Yue-Hang Xu; MA Beilstein; Patricia K Sonsalla; Kay Castagnoli; Neal Castagnoli; Michael A Schwarzschild
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2001;21(10):RC143.
2001: Kay Castagnoli; Salome Steyn; Jacobus P Petzer; Cornelis J Van Der Schyf; Neal Castagnoli
Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco.
Chemical research in toxicology 2001;14(5):523-7.
2001: S J Steyn; Kay Castagnoli; Salome Steyn; Neal Castagnoli
Selective inhibition of MAO-B through chronic low-dose (R)-deprenyl treatment in C57BL/6 mice has no effect on basal neostriatal dopamine levels.
Experimental neurology 2001;168(2):434-6.
2000: X Liu; Kay Castagnoli; Cornelis J Van Der Schyf; Neal Castagnoli
Studies on the in vivo biotransformation of the tobacco alkaloid beta-nicotyrine.
Chemical research in toxicology 2000;13(5):336-41.
2000: Jacobus P Petzer; Jacobus J Bergh; Lodewyk J Mienie; Neal Castagnoli; Cornelis J Van Der Schyf
Metabolic defects caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and by HPTP (the tetrahydropyridinyl analog of haloperidol), in rats.
Life sciences 2000;66(20):1949-54.
2000: Cornelis J Van Der Schyf; Kay Castagnoli; S Palmer; L Hazelwood; Neal Castagnoli
Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum.
Neurotoxicity research 2000;1(4):261-9.
2000: A A Khalil; Salome Steyn; Neal Castagnoli
Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves.
Chemical research in toxicology 2000;13(1):31-5.
1999: J Yu; Neal Castagnoli
Synthesis and monoamine oxidase B substrate properties of 1-methyl-4-heteroaryl-1,2,3,6-tetrahydropyridines.
Bioorganic & medicinal chemistry 1999;7(12):2835-42.
1999: H Inoue; Kay Castagnoli; Cornelis J Van Der Schyf; S Mabic; Kazuo Igarashi; Neal Castagnoli
Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives.
The Journal of pharmacology and experimental therapeutics 1999;291(2):856-64.
1999: Linda Truong; S m Pond; HR Cartwright; DA McRitchie; Neal Castagnoli; Cornelis J Van Der Schyf
Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol.
Experimental neurology 1999;158(1):155-63.
1999: X Liu; L Zang; Cornelis J Van Der Schyf; K Igarashi; Kay Castagnoli; Neal Castagnoli
Studies on the pyrrolinone metabolites derived from the tobacco alkaloid 1-methyl-2-(3-pyridinyl)pyrrole (beta-nicotyrine).
Chemical research in toxicology 1999;12(6):508-12.
1999: S K Nimkar; S Mabic; A H Anderson; S L Palmer; T H Graham; M de Jonge; L Hazelwood; S J Hislop; Neal Castagnoli
Studies on the monoamine oxidase-B-catalyzed biotransformation of 4-azaaryl-1-methyl-1,2,3,6-tetrahydropyridine derivatives.
Journal of medicinal chemistry 1999;42(10):1828-35.
1999: J Yu; Neal Castagnoli
Synthesis and MAO-B substrate properties of 1-methyl-4-heteroaryl-1,2,3,6-tetrahydropyridines.
Bioorganic & medicinal chemistry 1999;7(2):231-9.
1999: Kay Castagnoli; S Palmer; Neal Castagnoli
Neuroprotection by (R)-deprenyl and 7-nitroindazole in the MPTP C57BL/6 mouse model of neurotoxicity.
Neurobiology (Budapest, Hungary) 1999;7(2):135-49.
1999: Lodewyk J Mienie; Jacobus J Bergh; Jeffrey R Bloomquist; Neal Castagnoli; Salome Steyn; Cornelis J Van Der Schyf
p-Fluorophenylglycine in the urine of baboons treated with HPTP, the tetrahydropyridine analog of haloperidol.
Life sciences 1999;65(5):535-42.
1999: Neal Castagnoli; Kay Castagnoli; Cornelis J Van Der Schyf; E Usuki; Kazuo Igarashi; Salome Steyn; Richard R Riker
Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins.
Polish journal of pharmacology 1999;51(1):31-8.
1998: DA McRitchie; HR Cartwright; S m Pond; Cornelis J Van Der Schyf; Neal Castagnoli; D G van der Nest; Linda Truong
The midbrain dopaminergic cell groups in the baboon Papio ursinus.
Brain research bulletin 1998;47(6):611-23.
1998: Z Zhao; S Mabic; Simon Kuttab; C Franot; Kay Castagnoli; Neal Castagnoli
Rat liver microsomal enzyme catalyzed oxidation of 1-cyclopropyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Bioorganic & medicinal chemistry 1998;6(12):2531-9.
1998: E Usuki; Cornelis J Van Der Schyf; Neal Castagnoli
Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP.
Drug metabolism reviews 1998;30(4):809-26.
1998: C Franot; S Mabic; Neal Castagnoli
Chemical model studies on the monoamine oxidase-B catalyzed oxidation of 4-substituted 1-cyclopropyl-1,2,3,6-tetrahydropyridines.
Bioorganic & medicinal chemistry 1998;6(3):283-91.
1998: Y X Wang; S Mabic; Neal Castagnoli
1-Methyl-3-pyrrolines and 2-methylisoindolines: new classes of cyclic tertiary amine monoamine oxidase B substrates.
Bioorganic & medicinal chemistry 1998;6(2):143-9.
1997: Donato A Di Monte; J E Royland; A Anderson; Kay Castagnoli; Neal Castagnoli; J William Langston
Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity.
Journal of neurochemistry 1997;69(4):1771-3.
1997: Neal Castagnoli; John M Rimoldi; Jeffrey R Bloomquist; Kay Castagnoli
Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes.
Chemical research in toxicology 1997;10(9):924-40.
1997: C Franot; S Mabic; Neal Castagnoli
Chemical model studies on the monoamine oxidase-B catalyzed oxidation of 4-substituted 1-methyl-1,2,3,6-tetrahydropyridines.
Bioorganic & medicinal chemistry 1997;5(8):1519-29.
1997: Y X Wang; Neal Castagnoli
Potential latent nitrogen mustard derivatives designed to target monoamine oxidase rich cells.
Bioorganic & medicinal chemistry 1997;5(7):1321-5.
1997: S L Palmer; S Mabic; Neal Castagnoli
Probing the active sites of monoamine oxidase A and B with 1,4-disubstituted tetrahydropyridine substrates and inactivators.
Journal of medicinal chemistry 1997;40(13):1982-9.
1997: Douglas W Oliver; Irene C Dormehl; Cornelis J Van Der Schyf; J L Neumeyer; N Hugo; R Keeve; N T Rossouw; H W Müller-Gärtner; Neal Castagnoli
Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission computed tomographic study.
Arzneimittel-Forschung 1997;47(6):692-9.
1997: Kay Castagnoli; S Palmer; A Anderson; T Bueters; Neal Castagnoli
The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Chemical research in toxicology 1997;10(4):364-8.
1997: Neal Castagnoli; Kay Castagnoli
Metabolic bioactivation reactions potentially related to drug toxicities.
NIDA research monograph 1997;173():85-105.
1997: Lodewyk J Mienie; Jacobus J Bergh; E Van Staden; Salome Steyn; S m Pond; Neal Castagnoli; Cornelis J Van Der Schyf
Metabolic defects caused by treatment with the tetrahydropyridine analog of haloperidol (HPTP), in baboons.
Life sciences 1997;61(3):265-72.
1996: Cornelis J Van Der Schyf; Irene C Dormehl; Douglas W Oliver; N Hugo; R Keeve; H W Müller-Gärtner; S m Pond; Neal Castagnoli
Long-term treatment with the tetrahydropyridine analog (HPTP) of haloperidol influences dopamine ligand binding in baboon brain. An [123I]iodobenzamide (IBZM) SPECT study.
Brain research. Molecular brain research 1996;43(1-2):251-8.
1996: P Flaherty; Kay Castagnoli; Y X Wang; Neal Castagnoli
Synthesis and selective monoamine oxidase B-inhibiting properties of 1-methyl-1,2,3,6-tetrahydropyrid-4-yl carbamate derivatives: potential prodrugs of (R)- and (S)-nordeprenyl.
Journal of medicinal chemistry 1996;39(24):4756-61.
1996: S Mabic; Neal Castagnoli
Assessment of structural requirements for the monoamine oxidase-B-catalyzed oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridine derivatives related to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Journal of medicinal chemistry 1996;39(19):3694-700.
1996: S K Nimkar; A H Anderson; John M Rimoldi; M Stanton; Kay Castagnoli; S Mabic; Y X Wang; Neal Castagnoli
Synthesis and monoamine oxidase B catalyzed oxidation of C-4 heteroaromatic substituted 1,2,3,6-tetrahydropyridine derivatives.
Chemical research in toxicology 1996;9(6):1013-22.
1996: A H Anderson; S Kuttab; Neal Castagnoli
Deuterium isotope effect studies on the MAO-B catalyzed oxidation of 4-benzyl-1-cyclopropyl-1,2,3,6-tetrahydropyridine.
Biochemistry 1996;35(10):3335-40.
1996: K M Avent; E Usuki; Darryl W Eyles; R Keeve; Cornelis J Van Der Schyf; Neal Castagnoli; S m Pond
Haloperidol and its tetrahydropyridine derivative (HPTP) are metabolized to potentially neurotoxic pyridinium species in the baboon.
Life sciences 1996;59(17):1473-82.
1996: L Brand; Douglas W Oliver; Cornelis J Van Der Schyf; S m Pond; Neal Castagnoli
Dopamine receptor binding of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)- 4-oxobutyl]-1,2,3,6-tetrahydropyridine (HPTP), an intermediate metabolite of haloperidol.
Life sciences 1996;59(10):815-20.
1995: John M Rimoldi; Y X Wang; S K Nimkar; S H Kuttab; A H Anderson; H Burch; Neal Castagnoli
Probing the mechanism of bioactivation of MPTP type analogs by monoamine oxidase B: structure-activity studies on substituted 4-phenoxy-, 4-phenyl-, and 4-thiophenoxy-1-cyclopropyl-1,2,3,6-tetrahydropyridines.
Chemical research in toxicology 1995;8(5):703-10.
1995: A S Kalgutkar; Neal Castagnoli
Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism.
Medicinal research reviews 1995;15(4):325-88.
1995: Y X Wang; Neal Castagnoli
Studies on the monoamine oxidase (MAO)-catalyzed oxidation of phenyl-substituted 1-methyl-4-phenoxy-1,2,3,6-tetrahydropyridine derivatives: factors contributing to MAO-A and MAO-B selectivity.
Journal of medicinal chemistry 1995;38(11):1904-10.
1994: S Kuttab; A Kalgutkar; Neal Castagnoli
Mechanistic studies on the monoamine oxidase B catalyzed oxidation of 1,4-disubstituted tetrahydropyridines.
Chemical research in toxicology 1994;7(6):740-4.
1994: Jeffrey R Bloomquist; E King; A Wright; C Mytilineou; K Kimura; Kay Castagnoli; Neal Castagnoli
1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies.
The Journal of pharmacology and experimental therapeutics 1994;270(2):822-30.
1994: Cornelis J Van Der Schyf; Kay Castagnoli; E Usuki; H G Fouda; John M Rimoldi; Neal Castagnoli
Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice.
Chemical research in toxicology 1994;7(3):281-5.
1994: A S Kalgutkar; Kay Castagnoli; A Hall; Neal Castagnoli
Novel 4-(aryloxy)tetrahydropyridine analogs of MPTP as monoamine oxidase A and B substrates.
Journal of medicinal chemistry 1994;37(7):944-9.
1994: H Rollema; M Skolnik; J D'Engelbronner; K Igarashi; E Usuki; Neal Castagnoli
MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies.
The Journal of pharmacology and experimental therapeutics 1994;268(1):380-7.
1992: Z Zhao; D Dalvie; N Naiman; Kay Castagnoli; Neal Castagnoli
Design, synthesis, and biological evaluation of novel 4-substituted 1-methyl-1,2,3,6-tetrahydropyridine analogs of MPTP.
Journal of medicinal chemistry 1992;35(23):4473-8.
1992: A S Kalgutkar; Neal Castagnoli
Synthesis of novel MPTP analogs as potential monoamine oxidase B (MAO-B) inhibitors.
Journal of medicinal chemistry 1992;35(22):4165-74.
1992: Kazuo Igarashi; Neal Castagnoli
Determination of the pyridinium metabolite derived from haloperidol in brain tissue, plasma and urine by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1992;579(2):277-83.
1992: L Hall; S Murray; Kay Castagnoli; Neal Castagnoli
Studies on 1,2,3,6-tetrahydropyridine derivatives as potential monoamine oxidase inactivators.
Chemical research in toxicology 1992;5(5):625-33.
1992: Z Y Zhao; Neal Castagnoli; George A Ricaurte; T Steele; M Martello
Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)methamphetamine].
Chemical research in toxicology 1992;5(1):89-94.
1991: B Subramanyam; S m Pond; Darryl W Eyles; H A Whiteford; H G Fouda; Neal Castagnoli
Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol.
Biochemical and biophysical research communications 1991;181(2):573-8.
1991: Z Y Zhao; L Y Leung; A Trevor; Neal Castagnoli
C-formylation in the presence of rat brain mitochondria of the 2,3,4,5-tetrahydropyridinium metabolite derived from the psychotomimetic drug phencyclidine.
Chemical research in toxicology 1991;4(4):426-9.
1991: B Subramanyam; Thomas Woolf; Neal Castagnoli
Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite.
Chemical research in toxicology 1991;4(1):123-8.
1990: S Ottoboni; T J Carlson; William F Trager; Kay Castagnoli; Neal Castagnoli
Studies on the cytochrome P-450 catalyzed ring alpha-carbon oxidation of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Chemical research in toxicology 1990;3(5):423-7.
1990: H Rollema; E A Johnson; Raymond G Booth; P Caldera; P Lampen; S K Youngster; A J Trevor; N Naiman; Neal Castagnoli
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
Journal of medicinal chemistry 1990;33(8):2221-30.
1990: N Naiman; H Rollema; E Johnson; Neal Castagnoli
Studies on 4-benzyl-1-methyl-1,2,3,6-tetrahydropyridine, a nonneurotoxic analogue of the parkinsonian inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Chemical research in toxicology 1990;3(2):133-8.
1990: B Subramanyam; H Rollema; T Woolf; Neal Castagnoli
Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats.
Biochemical and biophysical research communications 1990;166(1):238-44.
1989: H Rollema; G M Alexander; J R Grothusen; F F Matos; Neal Castagnoli
Comparison of the effects of intracerebrally administered MPP+ (1-methyl-4-phenylpyridinium) in three species: microdialysis of dopamine and metabolites in mouse, rat and monkey striatum.
Neuroscience letters 1989;106(3):275-81.
1989: M K Shigenaga; B H Kim; P Caldera-Munoz; T Cairns; Peyton Jacob; A J Trevor; Neal Castagnoli
Liver and lung microsomal metabolism of the tobacco alkaloid beta-nicotyrine.
Chemical research in toxicology 1989;2(5):282-7.
1989: S Ottoboni; P Caldera; A Trevor; Neal Castagnoli
Deuterium isotope effect measurements on the interactions of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidase B.
The Journal of biological chemistry 1989;264(23):13684-8.
1989: E A Johnson; E Y Wu; H Rollema; Raymond G Booth; A J Trevor; Neal Castagnoli
1-methyl-4-phenylpyridinium (MPP+) analogs: in vivo neurotoxicity and inhibition of striatal synaptosomal dopamine uptake.
European journal of pharmacology 1989;166(1):65-74.
1989: Raymond G Booth; Neal Castagnoli; H Rollema
Intracerebral microdialysis neurotoxicity studies of quinoline and isoquinoline derivatives related to MPTP/MPP+.
Neuroscience letters 1989;100(1-3):306-12.
1989: Raymond G Booth; A Trevor; T P Singer; Neal Castagnoli
Studies on semirigid tricyclic analogues of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Journal of medicinal chemistry 1989;32(2):473-7.
1988: H Rollema; Raymond G Booth; Neal Castagnoli
In vivo dopaminergic neurotoxicity of the 2-beta-methylcarbolinium ion, a potential endogenous MPP+ analog.
European journal of pharmacology 1988;153(1):131-4.
1988: A J Trevor; Neal Castagnoli; T P Singer
The formation of reactive intermediates in the MAO-catalyzed oxidation of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Toxicology 1988;49(2-3):513-9.
1988: E Wu; T Shinka; P Caldera-Munoz; H Yoshizumi; A Trevor; Neal Castagnoli
Metabolic studies on the nigrostriatal toxin MPTP and its MAO B generated dihydropyridinium metabolite MPDP+.
Chemical research in toxicology 1988;1(3):186-94.
1988: M K Shigenaga; A J Trevor; Neal Castagnoli
Metabolism-dependent covalent binding of (S)-[5-3H]nicotine to liver and lung microsomal macromolecules.
Drug metabolism and disposition: the biological fate of chemicals 1988;16(3):397-402.
1988: T P Singer; Rona R Ramsay; K McKeown; A Trevor; Neal Castagnoli
Mechanism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Toxicology 1988;49(1):17-23.
1988: L A Peterson; Neal Castagnoli
Regio- and stereochemical studies on the alpha-carbon oxidation of (S)-nicotine by cytochrome P-450 model systems.
Journal of medicinal chemistry 1988;31(3):637-40.
1988: M K Hoag; M Schmidt-Peetz; P Lampen; A Trevor; Neal Castagnoli
Metabolic studies on phencyclidine: characterization of a phencyclidine iminium ion metabolite.
Chemical research in toxicology 1988;1(2):128-31.
1988: Donato A Di Monte; T Shinka; M S Sandy; Neal Castagnoli; Martyn T Smith
Quantitative analysis of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolism in isolated rat hepatocytes.
Drug metabolism and disposition: the biological fate of chemicals 1988;16(2):250-5.
1987: T Shinka; Neal Castagnoli; E Y Wu; M K Hoag; A J Trevor
Cation-exchange high-performance liquid chromatography assay for the nigrostriatal toxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its monoamine oxidase B generated metabolites in brain tissues.
Journal of chromatography 1987;398():279-87.
1987: M K Hoag; A J Trevor; A Kalir; Neal Castagnoli
Phencyclidine iminium ion. NADPH-dependent metabolism, covalent binding to macromolecules, and inactivation of cytochrome(s) P-450.
Drug metabolism and disposition: the biological fate of chemicals 1987;15(4):485-90.
1987: A J Trevor; Neal Castagnoli; P Caldera; Rona R Ramsay; T P Singer
Bioactivation of MPTP: reactive metabolites and possible biochemical sequelae.
Life sciences 1987;40(8):713-9.
1987: L A Peterson; A Trevor; Neal Castagnoli
Stereochemical studies on the cytochrome P-450 catalyzed oxidation of (S)-nicotine to the (S)-nicotine delta 1'(5')-iminium species.
Journal of medicinal chemistry 1987;30(2):249-54.
1987: Donato A Di Monte; G Ekström; T Shinka; Martyn T Smith; A J Trevor; Neal Castagnoli
Role of 1-methyl-4-phenylpyridinium ion formation and accumulation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity to isolated hepatocytes.
Chemico-biological interactions 1987;62(2):105-16.
1986: E Y Wu; K Chiba; A J Trevor; Neal Castagnoli
Interactions of the 1-methyl-4-phenyl-2,3-dihydropyridinium species with synthetic dopamine-melanin.
Life sciences 1986;39(18):1695-700.
1985: L A Peterson; P S Caldera; A Trevor; K Chiba; Neal Castagnoli
Studies on the 1-methyl-4-phenyl-2,3-dihydropyridinium species 2,3-MPDP+, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Journal of medicinal chemistry 1985;28(10):1432-6.
1985: J Weissman; A Trevor; K Chiba; L A Peterson; P Caldera; Neal Castagnoli; T Baillie
Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by liver homogenate fractions.
Journal of medicinal chemistry 1985;28(8):997-1001.
1985: K Chiba; L A Peterson; K P Castagnoli; A J Trevor; Neal Castagnoli
Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Drug metabolism and disposition: the biological fate of chemicals 1985;13(3):342-7.
1984: M K Hoag; A J Trevor; Y Asscher; J Weissman; Neal Castagnoli
Metabolism-dependent inactivation of liver microsomal enzymes by phencyclidine.
Drug metabolism and disposition: the biological fate of chemicals 1984;12(3):371-5.
1982: D P Ward; A J Trevor; A Kalir; J D Adams; T A Baillie; Neal Castagnoli
Metabolism of phencyclidine. The role of iminium ion formation in covalent binding to rabbit microsomal protein.
Drug metabolism and disposition: the biological fate of chemicals 1982;10(6):690-5.
1982: D Ward; A Kalir; A Trevor; J Adams; T Baillie; Neal Castagnoli
Metabolic formation of iminium species: metabolism of phencyclidine.
Journal of medicinal chemistry 1982;25(5):491-2.